Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The "inactive patch-University of California, San Francisco-postoperative pain" refers to a placebo control used in a Phase 4 clinical trial conducted by the University of California, San Francisco (UCSF). This inert transdermal patch was designed to match the appearance of a 25 mcg/hr fentanyl patch (Duragesic) to maintain blinding in a study evaluating the efficacy of prophylactic transdermal fentanyl for early postoperative pain management. The trial specifically targeted women undergoing mastectomy with immediate TRAM (transverse rectus abdominis myocutaneous) or DIEP (deep inferior epigastric perforator) flap reconstruction, comparing the patch's effectiveness as a bridge between epidural and oral analgesia. As a placebo, the patch contains no active pharmaceutical ingredients and serves as a comparator to assess the therapeutic effect and side profile of fentanyl in this surgical population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inactive patch-University of California, San Francisco-postoperative pain.